LianBio (LIAN) Announces CFO Departure

LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that Yi Larson, Chief Financial Officer, has resigned from LianBio to pursue other opportunities, effective December 19, 2023.

In connection with her departure, the LianBio Board of Directors has appointed Ehong (Maggie) Gu, current VP, Head of Global Finance, as Interim Chief Financial Officer.

“We are grateful to Yi for her many contributions to strategic initiatives at LianBio and wish her continued success in her next role,” said Konstantin Poukalov, Executive Chairman of the LianBio Board of Directors.

You May Also Be Interested In

• Lowe's names five executive vice presidents effective Sept. 1
• Virtus Convertible & Income Fund declares preferred share distribution
• Systech launches TraceIQ pharma traceability platform with AI tools